Lives are being saved, and many others are being changed dramatically, by current GLP-1 therapies like tirzepatide, which has helped many patients treat type 2 diabetes and sleep apnea, and also lose weight. It has been a long road from bench research to clinical trials to the health care market, but patients are now benefitting more than ever, according to a leading scientist who served as the keynote speaker for the second annual Dean’s Lecture and Bold Science Symposium, “Metabolism Research from Bench to Bedside.” Daniel Skovronsky, M.D., Ph.D., chief scientific officer and executive vice president of science and technology at Eli Lilly and Company and president of Research Laboratories and Lilly Immunology, was the Dean’s Lecturer on April 14 at the North Campus Research Complex Dining Hall.

University of Michigan Health experts to discuss medications such as Wegovy, Ozempic, Zepbound and more